These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Not reported Terminated||2006-002696-40||A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Multiple Doses of ACH-0137171 in Subjects with...||2007-02-08||due-trials|
|Listed as ongoing, but also has a completion date and reported results||2006-005968-13||A 14-Day, Randomized, Double-Blind, Comparative Viral Kinetic Study of Elvucitabine Versus Lamivudine Administered Once Daily to HIV-1 Infected Subjects with a Documented M184V Variant||2007-11-20||bad-data|
|Listed as ongoing, but also has a completion date and reported results||2006-006194-25||An open-label, 48-week extension study of elvucitabine administered in combination with background antiretroviral agents in subjects who have completed 14 days of treatment in Protocol ACH443-014A||2008-10-23||bad-data|
|Ongoing, reported early||2010-022092-65||A phase IIa, randomized, double-blind (subject and investigator blind, sponsor open) placebo-controlled trial to evaluate the safety, tolerability and antiviral activity of oral ACH-0141625 in combina...||not-yet-due|
|Listed as ongoing, but also has a completion date||2016-003525-42||A Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients with Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproli...||2019-01-09||bad-data|
|Ongoing||2016-003526-16||A Phase 2 Open-label Study of ACH-0144471 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy||not-yet-due|
|Ongoing||2017-000663-33||A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients with C3 Glomerulopathy (C3G)||not-yet-due|
|Other||2017-002674-39||An Open-Label Phase 2 Proof-of-Concept Study in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated with ACH-0144471||not-yet-due|